Director Wendy Yarno gains 2,954 Tarsus (TARS) shares from RSU grant

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director Wendy L. Yarno acquired 2,954 shares of common stock through the settlement of vested Restricted Stock Units (RSUs). Each RSU converted into one share of common stock, reflecting compensation for her service as a non-employee director. The RSUs were granted on June 12, 2025 and vested in full on the one-year anniversary of the grant date, subject to continuous service. Following this RSU settlement, Yarno directly holds 16,654 shares of Tarsus Pharmaceuticals common stock, and the RSU balance from this grant is now fully settled.

Insider Trade Summary

2,954 shares exercised/converted

Mixed 2 txns

Insider YARNO WENDY L

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	2,954	$0.00	--
Exercise	Common Stock	2,954	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 16,654 shares (Direct, null)

Footnotes (1)

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Each RSU represents a contingent right to receive one share of the Company's common stock. RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Key Figures

RSUs settled: 2,954 shares Shares held after transaction: 16,654 shares RSU-to-share ratio: 1 RSU : 1 share +2 more

5 metrics

RSUs settled 2,954 shares Vested RSUs converted to common stock on June 12, 2026

Shares held after transaction 16,654 shares Director Wendy L. Yarno direct Tarsus common stock holdings post-settlement

RSU-to-share ratio 1 RSU : 1 share Each Restricted Stock Unit represents one Tarsus common share

Exercise price per RSU $0.00 per unit RSUs settled into shares at no cash exercise price

Exercise transactions 1 exercise, 2,954 shares Form 4 transaction summary exerciseCount and exerciseShares

Key Terms

Restricted Stock Units, contingent right, non-employee director, derivative exercise/conversion, +1 more

5 terms

Restricted Stock Units financial

"The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Company's common stock."

non-employee director financial

"RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director"

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YARNO WENDY L

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		M(1)		2,954	A	(1)	16,654	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	06/12/2026		M			2,954	(3)	(3)	Common Stock	2,954	$0	0	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

2. Each RSU represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Tarsus (TARS) director Wendy L. Yarno report?

Wendy L. Yarno reported acquiring 2,954 Tarsus common shares through settlement of vested RSUs. These Restricted Stock Units converted into shares as part of her non-employee director compensation for service tied to the company’s 2025 annual stockholder meeting.

How many Tarsus (TARS) shares does Wendy L. Yarno hold after this Form 4?

After the RSU settlement, Wendy L. Yarno directly holds 16,654 shares of Tarsus common stock. This total reflects the addition of 2,954 shares issued upon vesting and settlement of her director RSU award granted in June 2025.

Was Wendy L. Yarno’s Tarsus (TARS) transaction an open-market buy or sale?

The transaction was not an open-market buy or sale. It reflects the exercise and settlement of 2,954 vested Restricted Stock Units into common shares, a compensation-related event tied to her service as a non-employee director of Tarsus Pharmaceuticals.

What are the terms of the Tarsus (TARS) RSUs reported by Wendy L. Yarno?

The RSUs were granted on June 12, 2025 in connection with Wendy L. Yarno’s service as a non-employee director. They vest in full on the one-year anniversary of the grant date, contingent on her continuous service on Tarsus’s board.

How many RSUs did Wendy L. Yarno settle into Tarsus (TARS) shares?

She settled 2,954 Restricted Stock Units into 2,954 shares of Tarsus common stock. Each RSU represented a contingent right to receive one common share upon vesting, consistent with the company’s director equity compensation structure.